COVID-19

Marta Ortega-Valle, founder of GreenLight Biosciences, talks to Elemental about mRNA and its potential to treat or prevent a whole range of conditions.

Marta Ortega-Valle, founder of GreenLight Biosciences, talks to Elemental about mRNA and its potential to treat or prevent a whole range of conditions in the future. Extracts from the article are below:

“In a way, we can produce medicines inside the body,” says Marta Ortega-Valle, founder of GreenLight, a biotech company that manufactures lab-produced RNA. “We could, instead of manufacturing proteins outside of patients, create them inside the body, using your own cells and the same system your body already has.”…

The vaccines may be the first publicly available pharmaceuticals to use mRNA, but they won’t be the last. Not by a long shot. GreenLight is currently working with the Gates Foundation to develop an mRNA-based treatment for sickle cell anemia. Research has been done into the potential for it to be used as an anti-aging therapy. The list of conditions and diseases that could theoretically be treated or prevented using mRNA vaccines and medicines is long…

Ortega-Valle and many in the science community believe the next frontier of medicine is based in mRNA. And now we’re expected to get there a lot faster. “I think that we’re experiencing an acceleration that was not in the plan,” she says. “My guess is that without the pandemic, a commercial vaccine based on mRNA would have taken many years, if it ever happened. Now we’ve done it, and it opens the door to more.”

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

the FDA had informed the company that it would not need to redo safety trials if all of the vaccine ingredients were the same and only the viral sequence was changed.

It’s likely the company’s drug candidate will act as a second-generation vaccine that could improve upon and supplement products already on the market.

Andrey Zarur, CEO of GreenLight Biosciences, wrote for STAT about the Covid-19 vaccine supply chain.

GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19.

GreenLight Biosciences spoke to the Financial Times about the vaccine supply issues for the Covid-19 vaccine

GreenLight Biosciences spoke to Mail Online about the vaccine supply issues in rolling out the Covid-19 vaccine

GreenLight Biosciences spoke to Technology Review about the vaccine ingredients for Pfizer’s Covid-19 vaccine, including messenger RNA.

GreenLight CEO, Andrey Zarur, spoke to the Financial Times about the Covid-19 vaccine manufacturing delays, with the hold up leaving the UK with fewer vaccines dosages than it had hoped.

GreenLight CEO, Andrey Zarur, spoke to Investor’s Business Daily about the Covid-19 vaccine manufacturing challenge, with billions around the world in need.

With manufacturing capacity in the news following the announcement of successful Covid-19 vaccine trials, Greenlight Biosciences CEO Andrey Zarur explains to Biospace the potential of the messenger RNA vaccine